Trials / Unknown
UnknownNCT05837689
Minimal Residual Disease Quantification by Next-generation Sequencing in Pediatric B-ALL Children Patients Treated With Blinatumomab Consolidation
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (estimated)
- Sponsor
- Xiaojun Xu · Academic / Other
- Sex
- All
- Age
- 1 Year – 18 Years
- Healthy volunteers
- Not accepted
Summary
A retrospective analysis to investigate pediatric B-cell acute lymphoblastic leukemia patients who were treated with blinatumomab for consolidation, and who were detected as minimal residual disease (MRD) positive by next generation sequencing (NGS). The efficacy of blinatumomab clearing MRD detected by NGS will be analyzed, in order to see the potential of using NGS to guide MRD eradication by blinatumomab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Blinatumomab | IV |
Timeline
- Start date
- 2023-04-01
- Primary completion
- 2023-04-01
- Completion
- 2023-04-01
- First posted
- 2023-05-01
- Last updated
- 2023-05-01
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05837689. Inclusion in this directory is not an endorsement.